|
| Status |
Public on May 03, 2024 |
| Title |
Adagrasib_100mpk_BI3406_50mpk_B12 |
| Sample type |
SRA |
| |
|
| Source name |
lung carcinoma
|
| Organism |
Homo sapiens |
| Characteristics |
tissue: lung carcinoma
cell line: NCI-H2122
cell type: lymphoblast
treatment: Adagrasib_100mpk_BI3406_50mpk
|
| Treatment protocol |
All mice had been treated with Adagrasib previously for 15 days before re-randomizing into 2 new groups: Group A = 8 mice were treated with Adagrasib continuously for 35 further days and Group B = 7 mice were treated with Adagrasib+SOS1i BI-3406 for 35 days. Adagrasib dose = 100 mg/kg qd, SOS1i BI-3406 = 50 mg/kg, bid.
|
| Growth protocol |
The cell lines were grown in the media recommended by the vendor and xenografted into mice.
|
| Extracted molecule |
total RNA |
| Extraction protocol |
Cells were lysed in TRI lysis reagent (Qiagen, #79306) according to the manufacturer's instructions. Total RNA was isolated with RNAeasy Mini Kit (Qiagen, #73404).
Tru-seq libraries were prepares using theTru-seq RNA Library Prep Kit v2 for Illumina from Lexogene (#015.96) according to manufacturer's instructions.
|
| |
|
| Library strategy |
RNA-Seq |
| Library source |
transcriptomic |
| Library selection |
cDNA |
| Instrument model |
NextSeq 2000 |
| |
|
| Data processing |
*library strategy: Tru-seq
Multiplexed samples were sequenced on an Illumina NextSeq 2000 system. Base-calling was performed using the Real-Time Analysis (RTA) software version 2.4.11. Conversion of the raw bcl2 output files to gzipped FASTQ files was performed using the bcl2fastq2 software version 2.20.0 provided by Illumina.
Data was processed with a pipeline building upon the implementation of the ENCODE "Long RNA-seq" pipeline: In brief, single-end sequencing reads were mapped against the Homo sapiens (human) genome hg38/GRCh38 (source 1000 Genomes Project - GRCh38_full_analysis_set_plus_decoy_hla.fa, excluding alternate contigs, chromosome mapping via grch38_ucsc2ensembl.txt) using the STAR (v2.5.2b) aligner allowing for soft clipping of adapter sequences. For quantification, transcript annotation files from Ensembl version 86 were used. Samples were quantified with the above annotations using featureCount (v1.5.1). Quality controls were implemented using FastQC (v0.11.5), picardmetrics (v0.2.4), and dupRadar (v1.0.0) at the respective steps. Finally, differential expression analysis was performed on the counts derived from featureCount using DESeq2
Assembly: GRCh38
Supplementary files format and content: tab-delimited text files include raw featureCounts values for each Sample
|
| |
|
| Submission date |
Feb 15, 2024 |
| Last update date |
May 03, 2024 |
| Contact name |
Daniel Gerlach |
| E-mail(s) |
daniel.gerlach@boehringer-ingelheim.com
|
| Organization name |
Boehringer Ingelheim RCV GmbH & Co KG
|
| Department |
Global Computational Biology and Digital Sciences
|
| Street address |
Dr.-Boehringer-Gasse 5-11
|
| City |
Vienna |
| ZIP/Postal code |
1121 |
| Country |
Austria |
| |
|
| Platform ID |
GPL30173 |
| Series (2) |
| GSE225061 |
Combination of a SOS1-KRAS interaction inhibitor with a KRASG12C inhibitor combination can address intrinsic and acquired resistance leading to stronger and more durable response |
| GSE255847 |
Combination of a SOS1-KRAS interaction inhibitor with a KRASG12C inhibitor combination can address intrinsic and acquired resistance leading to stronger and more durable response [Tru-seq] |
|
| Relations |
| BioSample |
SAMN39954629 |
| SRA |
SRX23635838 |
